Redeye briefly comments on the announcement of an indication expansion made by Initiator Pharma earlier today. We are encouraged to learn that the company will expand its two clinical assets, pudafensine and IP2018, to a broader sexual health franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications.
LÄS MER